Table 24Characteristics of included placebo-controlled trials of anticonvulsants, by drug

StudyArm Dose mg/day (N)Duration (Weeks)Population Trauma TypeBaseline PTSD SeverityaMean Age (Y)% F% Non-whiteRisk of Bias
Davis et al., 2008139Divalproex (1000 to 3000) (44)
Placebo (41)
8Male and female
Combat veterans
75.2 to 77.3552NRLow
Davidson et al., 2007140Tiagabine (4 to 16) (116)
Placebo (116)
12Male and female
Mixed
82.642.666NRMedium
Akuchekian et al., 2004137Topiramate (12.5 to 500) (34)
Placebo (33)
12Male
Combat veterans
49.8400100Medium
Tucker et al., 2007141Topiramate (25 to 400) (20)
Placebo (20)
12Male and female
Mixed
88.3 to 91.1417911Medium
Yeh et al., 2011138Topiramate (25 to 200) (17)
Placebo (18)
12Male and female
Mixed
66.1 to 78.84068NRMedium

CAPS = Clinician Administered PTSD Scale; F = female; mg = milligram; N = total number randomized/assigned to intervention and control groups; NR = not reported; PTSD = posttraumatic stress disorder; y = year

a

Data reported are mean CAPS or range of mean CAPS scores across groups unless otherwise specified.

From: Results

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) [Internet].
Comparative Effectiveness Reviews, No. 92.
Jonas DE, Cusack K, Forneris CA, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.